Member Info for hamcutlet

Article in todays Times https://www.thetimes.co.uk/article/biotech-company-opitbiotix-signs-sweet-deal-with-tata-chemicals-2ght3qbkk I assume we will receive an RNS at 7am A biotechnology company developing products to tackle obesity, high cholesterol and diabetes has struck a manufacturing agreement with Tata Chemicals. Under a deal set to be announced today, Optibiotix Health, the Aim-quoted company, has granted the rights to the Indian-listed food ingredients company, part of Tata Group, to produce a sugar from its cholesterol and blood pressure-lowering probiotic for use in food and over-the-counter products. The agreement builds on a deal in December between the company and Tata Chemicals to develop weight loss products for the Indian market.

hxxps://www.*************.com/views/30430/optibiotix-another-day-another-deal-o-hara-confirms-the-arm-model-buy OptiBiotix (OPTI) has announced another sales deal. Like others it is small to start with but will build up and this grows more and more reminiscent of the early days of ARM. Check out the Steve O'Hara quote at the end of the release. The latest deal is to supply three different products containing LPLDL®, with minimum initial purchase of 10,000 boxes of each, to Pharmabiota NZ Limited. n, based in New Zealand, was founded by pharmacist Peter Lagan to provide high quality and scientifically validated innovative products through its growing retail pharmacy partner network throughout New Zealand and Australia. The size of the deal, the release states: "This agreement covers the initial development and supply of three products, packaged and released by Pharmabiota, containing LPLDL® in different dosage forms and provides initial moderate levels of income, growing to six figure revenues in the second year, and a commitment of 10% annual growth. " The point is that Optibiotix is signing more and more deals like this at an accelerating rate. Expect more like this and a couple that are much bigger over the summer. each deal adds sod all to Optibiotix's fixed costs and is massively high margin. So at a certain point, the inflection point, the company heads into profit and thereafter as sales ramp up so do profits at a stunning rate. That is the ARM Model and you just do not see what is happening until it suddenly does but by then - if ARM is the precedent - the shares have already raced ahead. Steve O Hara noted in today's release: "This is a low risk, low cost approach, to accessing multiple consumer healthcare and pharmaceutical markets around the world. We are at the start of the commercialisation process but are really excited at the high level of interest in our products and the prospect of building multiple revenue streams, which if this strategy is successful, have the potential to cumulatively generate substantive seven figure revenues in the forthcoming years." Indeed. You will see more evidence that Optibiotix is delivering and this is no pipe dream over the summer. that makes the shares a very strong BUY at a 65p offer and at up to 80p. Our target remains to sell at well over 100p before Christmas. This will pay for the festive season in spades

can't buy any on IG ..." market in an non-dealable state !!"